Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2014Molecular and Clinical OncologyOpen Access

Ginsenoside Rg3 enhances the inhibitory effects of chemotherapy on esophageal squamous cell carcinoma in mice

View Full Paper
Ask AI
Bookmark
Share

Key result

Ginsenoside Rg3 combined with chemotherapy significantly inhibited tumor growth in mice with esophageal squamous cell carcinoma, achieving a 70.64% inhibitory rate compared to 59.67% with chemotherapy alone.

Why the study?

Does ginsenoside Rg3 combined with chemotherapy improve tumor inhibition in a mouse model of esophageal squamous cell carcinoma?

Population

20 female BALB/c nude mice, weighing 18-20 g and aged 5-6 weeks, with Eca-109 human esophageal squamous…

Comparison

Ginsenoside Rg3 combined with chemotherapy. vs Control group, ginsenoside Rg3 alone, and…

Design

Preclinical, randomly assigned to 4 treatment groups

Follow-up

21 days

Authors

LCLiang ChangBHBingjie HuoYLYalei Lv

Discussion

Loading...

Member takes

Overview

Should not yet alter clinical practice; leaves open translation of ginsenoside Rg3 adjunctive effects to human esophageal cancer trials.

Structured PICO

Does ginsenoside Rg3 combined with chemotherapy improve tumor inhibition in a mouse model of esophageal squamous cell carcinoma?

P
Population
20 female BALB/c nude mice with Eca-109 esophageal squamous cell carcinoma xenografts were treated and followed for 21 days.
I
Intervention
Ginsenoside Rg3 (6 mg/kg/day oral by gavage once daily for 3 weeks) combined with chemotherapy (paclitaxel 10 mg/kg/day + cisplatin 5 mg/kg/day intraperitoneally on days 1, 7, 14 and 21).
C
Comparator
Control group (saline), ginsenoside Rg3 alone (6 mg/kg/day), and chemotherapy alone (paclitaxel 10 mg/kg/day + cisplatin 5 mg/kg/day).
O
Outcome
Tumor volume (cm3) and tumor inhibitory rate at 21 days.surrogate

Main Result

Absolute Event Rate: 0.614% vs 2.367%

p-value: p=<0.0001

Ginsenoside Rg3 significantly enhances the antitumor efficacy of paclitaxel and cisplatin in a mouse model of esophageal squamous cell carcinoma by reducing tumor proliferation and microvascular density.

Limitations

  • Animal model results may not directly translate to human clinical efficacy
  • Small sample size of 5 mice per group

Cite This Study

Chang et al. (2014) studied Esophageal squamous cell carcinoma (ESCC) (n=20). Ginsenoside Rg3 combined with chemotherapy vs. Saline control, Rg3 alone, and chemotherapy alone was evaluated on Tumor volume (cm3) at day 21 (p=<0.0001). Ginsenoside Rg3 combined with chemotherapy significantly inhibited tumor growth in mice with esophageal squamous cell carcinoma, achieving a 70.64% inhibitory rate compared to 59.67% with chemotherapy alone.

synapsesocial.com/papers/6a7717f44fe2e6ffd8ec67b3https://doi.org/10.3892/mco.2014.355
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice2009 · 145 citations
  2. 2Synergistic effects of ginsenoside Rg3 and cyclophosphamine on tumor growth and angiogenesis in lung cancer2011 · 5 citations
  3. 3Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer2007 · 89 citations
  4. 4Ginsenoside Rg3 Prolongs Survival of the Orthotopic Hepatocellular Carcinoma Model by Inducing Apoptosis and Inhibiting Angiogenesis2019 · 29 citations
  5. 5Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model2014 · 32 citations